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Mitochondria are the primary site of cellular energy generation and reactive oxygen species (ROS) accumulation. Elevated ROS
levels are detrimental to normal cell function and have been linked to the pathogenesis of neurodegenerative disorders such as
Down’s syndrome (DS) and Alzheimer’s disease (AD). RCAN1 is abundantly expressed in the brain and overexpressed in brain of
DS andADpatients. Data from nonmammalian species indicates that increased RCAN1 expression results in alteredmitochondrial
function and that RCAN1may itself regulate neuronal ROS production. In this study, we have utilized mice overexpressing RCAN1
(RCAN1ox) and demonstrate an increased susceptibility of neurons from these mice to oxidative stress. Mitochondria from these
mice are more numerous and smaller, indicative of mitochondrial dysfunction, and mitochondrial membrane potential is altered
under conditions of oxidative stress. We also generated a PC12 cell line overexpressing RCAN1 (PC12RCAN1). Similar to RCAN1ox
neurons, PC12RCAN1 cells have an increased susceptibility to oxidative stress and produce more mitochondrial ROS. This study
demonstrates that increasing RCAN1 expression alters mitochondrial function and increases the susceptibility of neurons to
oxidative stress in mammalian cells. These findings further contribute to our understanding of RCAN1 and its potential role in
the pathogenesis of neurodegenerative disorders such as AD and DS.
1. Introduction
The RCAN1 (regulator of calcineurin 1) gene is located in
the 21q22.1-q22.2 region of human chromosome 21 and is
expressed primarily in brain, heart, and skeletal muscle [1]
and in endocrine tissues including the adrenal gland [2] and
pancreas [3]. RCAN1 is best characterized as an endogenous
inhibitor of the phosphatase calcineurin [4]. It exists as two
protein isoforms, named RCAN1.1 and RCAN1.4 depending
on exon at which transcription is initiated. Calcineurin itself
regulates the transcription of RCAN1.4, but not RCAN1.1, due
to the presence of NFAT initiation sites upstream of exon
4 [5]. In this respect, RCAN1.4 forms a negative feedback
loop in cells regulating calcineurin-dependent dephosphory-
lation. Furthermore, RCAN1.1, but not RCAN1.4, expression,
is induced by thyroid hormone [5]. These two isoforms
may have independent cell functions as our own research
has demonstrated that RCAN1.1 regulates exocytosis [6,
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7], learning, memory and synaptic transmission [8], 𝛽-cell
function and insulin secretion [3], and immune cell function
[9]. Short- or long-term expression of RCAN1.1 protects
against or promotes, respectively, neuronal cell apoptosis in
response to oxidative stress [10]. RCAN1.4, while typically
being expressed at lower levels than RCAN1.1, may also have
independent functions. RCAN1.4 gene expression is more
highly upregulated in response to oxidative stress, although
this does not correlate with increased protein expression
[11], and upregulation of RCAN1.4 is observed in peri-infarct
cortex of stroke [12]. Overexpression of RCAN1.4 exacerbates
Ca2+-induced apoptosis in neurons [13], while RCAN1.4
knockdown attenuates cell growth through the inhibition of
Ras signaling [14] and protects against apoptosis [15].
RCAN1.1 is overexpressed in the brains of both DS and
AD individuals [2, 4, 16]. RCAN1 is postulated to provide
a link between chronic stress and neurodegeneration [17]
and have an essential role in the pathogenesis of AD by
linking amyloid-𝛽 toxicity and tau hyperphosphorylation
[18]. The pathological hallmarks of AD are amyloid plaques
and hyperphosphorylated tau with neurofibrillary tangles.
More than 25 AD clinical trials targeting amyloid 𝛽 have
failed to show any significant reduction in disease burden
[19]. The fact that trials have shown clearance of amyloid 𝛽
deposits in the brains of AD subjects without impact on either
clinical disease progression or progression of tau aggregation
pathology [20] indicates that while amyloid pathology exists
in AD brains, it may not be the primary driver of sporadic
AD. Growing evidence supports the notion that tau can
drive AD and amyloid toxicity [21] and higher RCAN1, as
observed in AD brains [16], increases the phosphorylation of
tau [17]. This mechanism likely occurs through the increased
calcineurin inhibition in AD brains [22] and calcineurin
is responsible for tau dephosphorylation [23]. Furthermore,
RCAN1 expression correlates strongly with the amount of
neurofibrillary tangles observed in AD brains [24].
It is worth noting that most DS individuals experi-
ence seizures and all are mentally impaired and develop
Alzheimer’s-like neuropathology by their mid-30’s, charac-
terized by 𝛽-amyloid peptide-containing neuritic plaques,
tau-containing neurofibrillary tangles, basal forebrain cholin-
ergic neuron degeneration, and dementia [25]. Furthermore,
neuronal oxidative stress and mitochondrial dysfunction are
early hallmarks of both DS [26] and AD [27]. Mitochondria
are an essential intracellular organelle responsible for cellular
energy generation. Mitochondria are also the major site of
reactive oxygen species (ROS) which are produced primarily
as a byproduct of oxidative phosphorylation. Elevated ROS
levels and impaired mitochondrial function are seen in DS
cortical neurons in culture [28, 29] as is ROS accumulation
in brain tissue from individuals with DS [30] and from
Ts65Dn mice [31]. Mitochondrial size and number are also
altered in hippocampal neurons from AD patients [27]
and oxidative damage is a prominent and early feature of
vulnerable neurons in AD [32, 33]. Mitochondrial respiration
is impaired in transgenic AD mice overexpressing both
amyloid-𝛽 and tau, with tau preferentially impairing complex
I of the respiratory chain and amyloid-𝛽 blocking complex
IV-dependent respiration [34]. A significant decrease of
complex IV activity is observed in the cortical regions of
AD brains [35]. Additionally, RCAN1 expression is induced
in neurons by both amyloid-𝛽 and oxidative stress [2, 36].
RCAN1 also alters cellular susceptibility to oxidative stress
as neurons with no RCAN1 expression display an increased
resistance to damage by ROS [11].
Evidence from Drosophila melanogaster suggests that
nebula, the homolog of mammalian RCAN1, is involved
in the regulation of mitochondrial function [37]. Altered
expression of nebula inDrosophila neurons results in reduced
mitochondrial size, increased mitochondrial number, and
increased reactive oxygen species generation [37]. However,
whether the chronic overexpression of RCAN1, as occurred
in DS and AD brains, regulates mitochondria function in
mammalian cells remains unknown. In this study, we have
utilised multiple mammalian cell types commonly used
in the study of neuronal function to assess the effect of
chronically increased RCAN1 expression on mitochondrial
morphology and function, including ROS production, and
the susceptibility of neurons to damage from oxidative
stress. We demonstrate altered mitochondrial number and
size, increased mitochondrial ROS production, and altered
mitochondrial membrane potential in response to ROS in
cells overexpressing RCAN1. Furthermore, RCAN1 overex-
pression increases cellular susceptibility to oxidative stress by
reducing cell viability in response to increasing ROS levels.
Our findings have implications for neurodegeneration in DS
and AD in which RCAN1, mitochondrial dysfunction, and
oxidative stress are all thought to play a pathogenic role.
2. Methods
2.1. Mice. RCAN1 transgenic (RCAN1ox) mice were gener-
ated using the human RCAN1 cDNA encoding the exon 1
splice variant as previously described [6]. Use of mice was
approved by the Flinders University and Monash University
Animal Welfare Committees. All mice were maintained in
the Animal House at the Flinders Medical Centre or Monash
University. Mice were fed a normal chow diet and were on a
12-hour light/12-hour dark cycle.
2.2. Primary Neuron Culture. For isolation of mouse cor-
tical neurons,pregnant female mice were killed by cervical
dislocation at 14 to 16 days after coitus and the foetuses
were dissected from the uterine horns in dissecting solution





0.25mM HEPES, 0.12mM MgSO
4
, 0.26% (w/v) D-glucose,
0.3% (w/v) BSA, and pH 7.4). Foetuses were rapidly killed
by decapitation and the cerebral cortices were excised and
pooled in 15mL dissecting solution containing 0.25% (w/v)
trypsin (Invitrogen, Carlsbad, CA, USA) at 37∘C. After 20
minutes, digestion was terminated by the addition of 15mL
dissecting solution containing 0.01% DNase (Sigma-Aldrich,
St. Louis, MO, USA). The solution was mixed well and
the cells pelleted and resuspended in 2mL dissecting solu-
tion containing 0.02% (w/v) glycine max and 0.004% (w/v)
DNase.The cells were dissociated by passing through a blunt-
ended glass Pasteur pipette for 2 minutes. Finally, neuronal
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cells were collected after centrifugation at 500 g for 5 minutes
and resuspended in 10mL plating media (Neurobasal media,
Invitrogen, Carlsbad, CA, USA), 10% FCS, 2% B27 supple-
ment, 0.5mM glutamycin (SAFC Biosciences, Lenexa, KA,
USA), and 50 𝜇g/mL gentamicin (Invitrogen, Carlsbad, CA,
USA) before counting. Five hours after plating, the media
were changed to plating media without FCS. Half the media
was changed every two days during culture. All dishes and
plates used for culture were treated with 0.005% poly-L-
lysine for at least two hours before use (Sigma-Aldrich, St.
Louis, MO, USA). To obtain near pure neuronal cultures,
2.5 𝜇g/mL cytosine D-arabinofuranoside (Sigma-Aldrich, St.
Louis, MO, USA) was applied to cultures on day four after
plating for 24 hours. Experiments were performed on days
8-9 of cultures.
2.3. MTT Viability Assay. Primary cortical neurons were
grown at a density of 8×104 cells/cm2 in poly-L-lysine treated
plates for 9 days before treatment. PC12 cells were seeded
at 4 × 105 cells/well for 6 hours prior to treatment then






bromide) (Sigma) was added at a concentration of 500𝜇g/mL
to each well and incubated at 37∘C for 4 hours. Media were
discarded and cells were resuspended in 200𝜇L DMSO by
repeated pipetting to solubilize the formazan. Suspensions
were transferred to Eppendorf tubes and centrifuged at
12,000 g in a MiniSpin bench top microcentrifuge (Eppen-
dorf) for 4 minutes. 50 𝜇L supernatant was transferred in
triplicate to the wells of 96-well plate and absorbance was
measured at 590 nm on a Fluostar Optima plate reader (BMG
Lab Technologies).
2.4. Electron Microscopy. Adrenal medulla was dissected
from mice and whole tissue was fixed for 1 hour in EM fix-
ative (4% formaldehyde and 1.5% glutaraldehyde in sodium
cacodylate buffer, pH 7.2) and postfixed in 2% osmium
tetroxide in sodium cacodylate buffer. Fixed tissue was
stained with 2% uranyl acetate and dehydrated through
70%, 90%, and 100% ethanol. Tissue was processed through
1,2-epoxypropane, a 1 : 1 mixture of 1,2-epoxypropane and
Procure 812 resin (Electron Microscopy Sciences, USA), and
two changes of 100% resin. Tissue and resin were transferred
to Beem capsules and placed overnight at 90∘C. Survey
sections were stained with toluidine blue and 100 nm sections
were cut on a Porter-Blum ultramicrotome (Sorvall, USA)
using a diamond knife (Micro Star Technologies, USA).
Thin sections were stained with Reynold’s lead citrate and
examined on a Hitachi H-600 transmission electron micro-
scope (Hitachi, Japan). All analysis was done on chromaffin
cells photographed at 4000x magnification unless otherwise
mentioned. Electron micrographs were analysed by ImageJ
image analysis software. Within the adrenal sections, chro-
maffin cells were distinguished by their characteristic granule
morphology and are easily distinguished from cortical cells at
the ultrastructural level [38].Mitochondria were identified by
their characteristic, outer and inner membrane, and cristae.
Mitochondrial number was calculated utilizing the ImageJ
cell counting plugin while mitochondrial area was calculated
using the ImageJ free hand application.
2.5. Estimation of Mitochondrial Transmembrane Potential.
The ratiometric fluorescent dye JC-1 was used to provide
relative measurements of mitochondrial membrane potential
[39–41]. At depolarized potentials, JC-1 forms monomers
producing green fluorescence detectable at 530 nm. At higher
membrane potentials, JC-1 forms multimers (J-aggregates)
producing red fluorescence that is detectable at 590 nm.
Both the monomer and the J-aggregate were excited simul-
taneously at 488 nm. The ratio of fluorescence emission at
590 : 530 nmwas determined as an indicator of themitochon-
drial membrane potential [40]. Cultured adrenal chromaffin
cells were used for these measurements. Adrenal chromaffin
cells were cultured from adult mice as previously described
[6, 42]. Briefly, the adrenal medulla was dissected out in cold
Locke’s buffer (154mMNaCl, 5.6mMKCl, 3.6mMNaHCO
3
,
5.6mM D-Glucose, 5.0mM HEPES, and pH 7.4) and incu-
batedwith collagenase-A, (Roche, Germany) in Locke’s buffer
at a concentration of 3mg/mL, in a shaking water bath at
37∘C. The collagenase was diluted in cold Locke’s buffer,
and cells were pelleted and resuspended in DMEM medium
supplemented with 1% penicillin/streptomycin (Invitrogen,
Carlsbad, CA, USA) and 10% FCS (JRH Biosciences, Lenexa,
USA) and filtered through nylon mesh. Cells were pelleted,
resuspended in supplemented DMEM, and plated on 35mm
culture dishes and incubated at 37∘Cwith 5%CO
2
. Cells were
maintained in primary culture for 3-4 days prior to exper-
iments. Chromaffin cells were washed twice and incubated
in serum free culture media containing JC-1 (0.125 𝜇M) for
30min. The cultures were then rinsed and left in dye-free
media for 20 minutes at 37∘C before being subjected to real-
time imaging in a Leica SP5 Spectral Confocal Microscope
(Leica Microsystems, Wetzlar, Germany). High resolution
digital images were analyzed using ImageJ.
2.6. Generation of RCAN1-FLAGFusion Expression Construct.
Full length cDNA encoding RCAN1 fused to FLAG was
generated by PCR using the following primers: RCAN1-
5󸀠-utrF 5󸀠-gattccgagggggttaacggcgga-3󸀠 and RCAN1-3󸀠-
FLAGR 5󸀠-tcacttgtcatcgtcgtccttgtagtcgctgaggtggatcggcgtgt-3󸀠
(sequence encoding the FLAG tag is underlined whilst the
stop codon is in bold). Template cDNA used in the PCR
reaction was generated by RT-PCR of RNA extracted from
a Ntera 2/D1 (NT2) human cell line. The resulting 901 bp
PCR product had a FLAG tag sequence (DYKDDDDK)
incorporated in frame directly upstream of theRCAN1
stop codon and was cloned into pGEM-T Easy (Promega).
Sequence analysis carried out using T7 and SP6 primers
(Promega) confirmed that the epitope-tag was in frame
with the RCAN1 coding sequence. The 901 bp PCR product
was excised from pGEM-T utilizing the EcoR1 restriction
sites present on either side of the insert. The resulting
DNA fragment was ligated into the EcoR1 restriction site of
pcDNA3 (Invitrogen). As this ligation was not directional,
clones were screened by PCR amplification using the
T7 forward and the RCAN1-3󸀠-FLAGR primers. Those
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clones with correct orientation produced a 958 bp PCR
product, whilst clones with incorrect orientation produced
a 57 bp product. For cell transfection experiments the
pcDNA3/RCAN1-FLAG construct was prepared using
an endo-free Qiagen Maxi prep. kit. The construct was
linearized prior to transfection by digestion with the
restriction endonuclease PvuI.
2.7. Generation of PC12 Cell Lines Stably Overexpressing
RCAN1. 7 𝜇g of linearized plasmidDNAwas transfected into
1.5 × 10
6 rat pheochromocytoma PC12 cells by electropo-
ration. As a control, untransfected PC12 cells were grown
on a separate plate. To select for transfectants, cells were
treated with Geneticin (G418) containing media replaced
every 48 hours for 10–15 days or until all the untransfected
PC12 cells on the control plate had died. Transfectants were
then grown in G418-free media and allowed to form colonies
which were picked and subsequently expanded. PC12 cells
were cultured in F-12 K containing 10% horse serum, 5% FCS,
1% Pen-Strep (penicillin-streptomycin), and 1% glutamine
(Invitrogen, Australia). Cells were grown at 37∘C in a 5%
CO
2
humidified environment 95% air and were grown to
80–90% confluency before being passaged. For passaging,
cells were treated with 0.125% trypsin (Invitrogen, Australia)
for 3 minutes, collected with fresh media, centrifuged at
400 g for 5 minutes, and seeded at a density of 2.5 × 105
cells/mL. Cells were plated out at a density of 2.5 × 103
cells/mL on 35mm culture dishes and allowed at least 24
hours to adhere to plates before being used for experiments.
In selected experiments, 10mM of N-acetyl-cysteine (Sigma,
Australia) was added to culture media for 24 hours before
experiments were performed.
2.8. RT-PCR andWestern Blot Analysis. To test for expression
of RCAN1-FLAG, RNA was extracted from cells grown to
confluence on a 6 cm plate using TRIzol reagent (Invitro-
gen). cDNA was generated by RT-PCR using Superscript III
enzyme (Invitrogen). PCR reactions were carried out using
RCAN1-5󸀠-utrF and RCAN1-3󸀠-FLAGR primers. RCAN1-
FLAGprotein expression levels were assessed byWestern blot
analysis. Protein was extracted from PC12 clones and run on
a 12% SDS-PAGE gel and transferred onto a PVDFmembrane
(Immobilon-P, Invitrogen). An 𝛼-FLAG antibody conjugated
to horseradish peroxidase (Sigma) was used to probe the
membrane at a dilution of 1 : 1000.
2.9. Measurement of ROS Production. Media were removed
from PC12 cells in culture dishes and replaced with warm
(37∘C) Krebs solution (140mM NaCl, 5mM KCl, 2mM
CaCl
2
, 1 mM MgCl
2
, 5mM D-Glucose, 10mM HEPES, and
pH 7.4).MitoSOXmitochondrial superoxide indicator (Invit-
rogen, Australia) was added to cells at a final concentration of
5 𝜇M. Cells were incubated for 10 minutes at 37∘C, protected
from light, and then gently washed three times with warm
Krebs solution. Fluorescence was viewed using an Olympus
IX71 fluorescence microscope (Olympus Ltd., Tokyo, Japan).
Images were captured at 20x magnification and at the same
exposure time for each experimental group. Images were
analysed using Image J analysis software (National Institutes
of Health, USA). Background fluorescence of each image
was measured in duplicate and removed from the mean
fluorescence intensity of cells to obtain final values of mean
cell fluorescence intensity.
2.10. Statistical Analysis. For individual comparisons, statis-
tical analysis of data was carried out using the 𝑡-test, two
samples assuming equal variances. Formultiple comparisons,
statistical analysis was performed using an ANOVA followed
by a Bonferroni multiple comparison test. All data are
expressed as means ± S.E.M. 𝑃 < 0.05 was considered
significant.
3. Results
3.1. Neurons Overexpressing RCAN1 Show Decreased Cell




. In order to investigate the
role of RCAN1 in oxidative stress and cell viability, primary
cultures of cortical neurons, prepared fromE15 RCAN1ox and





and cell viability was measured by MTT assay after
18 hours. Primary neurons derived from RCAN1ox mice





with 39.7 ± 0.4% of neurons viable versus





a larger difference (𝑃 < 0.0001) in neuronal viability between
the two populations; 31 ± 0.6% RCAN1ox neurons were
viable versus the 53.9 ± 1.9% of wild-type neurons (Figure 1).
Experiments were carried out on three independent cultures
with percentage cell viability calculated as a proportion of
the viability of untreated cells from the same genotype.
Interestingly, there was no difference between the viability





3.2. RCAN1 RegulatesMitochondrialMorphology. Alterations
in mitochondrial function may underlie the increased sus-
ceptibility to oxidative stress observed in primary RCAN1ox
neurons. Mitochondrial morphology is regulated by RCAN1
expression in Drosophila neurons [37]. We therefore con-
ducted an ultrastructural analysis of WT and RCAN1ox
mitochondria in chromaffin cells via electron microscopy.
Chromaffin cells are neuroendocrine cells and an accepted
model in neuronal studies that we have used previously [6, 7].
Their relative abundance in the adrenal medulla and the
ability to obtain these cells in a homogenous population and
to readily identify them at an ultrastructural level provide
an ideal model for the analysis of mitochondrial size and
number via electron microscopy. Mitochondrial appearance
was similar, with clearly visible cristae, in both WT and
RCAN1ox cells (Figures 2(a) and 2(b)). However, the number
of mitochondria was significantly increased (Figure 2(c),
𝑃 < 0.01) and the average mitochondrial area reduced
(Figure 2(d), 𝑃 < 0.05) in RCAN1ox cells compared to WT.
Analyzing the distribution of mitochondrial area in these
cells (Figure 2(e)) demonstrates that RCAN1ox cells had a
greater number of smaller mitochondria when compared





























. Primary neuronal cultures from E15 wild-type (light bars)




for 18 hours and cell viability was measured via
a standard MTT assay. 𝑛 = 4 neuronal cultures from individual wild-type and RCAN1ox mice. Data presented as a percentage of the number
of starting viable cells, error bars represent SEM, and ∗∗∗𝑃 < 0.001.
to wild-type controls. These results are consistent with the
observation of Chang and colleagues inDrosophila, where the
overexpression of RCAN1 resulted in altered mitochondrial
morphology due to mitochondrial fission [37].
3.3. RCAN1𝑜𝑥 Cells Have Altered Mitochondrial Membrane
Potential in Response to ROS. To further ascertain whether
mitochondrial function is altered by RCAN1 overexpression,
we evaluated mitochondrial membrane potential under vari-
ous conditions in WT and RCAN1ox chromaffin cells using
the fluorescent mitochondrial membrane potential marker,
JC-1. We found that mitochondrial membrane potential is
similar in both groups under basal conditions, with the mean
JC-1 fluorescence ratio being 2.1± 0.3 and 2.4± 0.4 (Figure 3)
in WT and RCAN1ox cells, respectively. No changes in JC-
1 fluorescence ratio were observed after depolarization of
the plasma membrane using a 56mM K+ solution, demon-
strating that the response of JC-1 is not influenced by
changes in plasma membrane potential. Depolarization of
the mitochondria was achieved by treatment with the K+
ionophore Valinomycin (500 nM; 10 minutes) which rapidly
reduced the JC-1 ratio to 0.48 ± 0.05 in WT cells and





(100 𝜇M: 60 minutes) resulted in a significant
difference in JC-1 fluorescence between WT and RCAN1ox
cells. The change in fluorescence in JC-1 fluorescent ratio





indicated a more severe effect on mitochondrial
membrane potential in RCAN1ox cells (2.2 ± 0.3WT versus
3.2 ± 0.5RCAN1ox, 𝑃 < 0.05).
3.4. Generation of PC12 Cells Stably Overexpressing RCAN1.
In order to confirm that the results seen in RCAN1ox cells are
not due to changes associated with developmental influences
from outside the cells being studied, we developed a PC12 cell
line overexpressing RCAN1 (PC12RCAN1 cells). Twenty-four
independent PC12 clones stably transfected with RCAN1-
FLAG (Figure 4(a)) were tested for expression of the con-
struct. All clones generated RNA transcripts of the RCAN1-
FLAG construct (three representative clones are shown in
Figure 4(b)). Protein expression levels were assessed byWest-
ern blot analysis. Of the nine clones tested, three expressed
the RCAN1-FLAG at equivalent levels (Figure 4(c)). Untrans-
fected PC12 cells were used as a negative control. Increased
RCAN1 protein expression in PC12RCAN1 cells was fur-
ther verified immunohistochemically using an anti-RCAN1
antibody (Figure 4(d)). These results confirmed the stable
overexpression of RCAN1 in PC12 cells and were hence used
for subsequent experiments.
3.5. RCAN1 Overexpression Increases Mitochondrial ROS
Production. ROS production was measured in control and
PC12RCAN1 cells usingMitoSOX Red, a mitochondrial super-
oxide indicator (Figures 5(a) and 5(b)). Mitochondrial ROS
production was increased in PC12RCAN1 cells in comparison
to control PC12 cells (Figure 5(c), 𝑃 < 0.001). ROS pro-
duction was decreased in PC12RCAN1cells treated with the
antioxidant N-acetylcysteine (NAC) compared to untreated
PC12RCAN1cells (𝑃 < 0.001). NAC treatment had no effect on
mitochondrial ROS production in control PC12 cells.










and viability measured similarly to our exper-
iments in RCAN1ox neurons. PC12RCAN1 cells and control





































































Figure 2: RCAN1 regulates mitochondrial morphology. Representative electron-micrographs from (a) wild-type and (b) RCAN1ox
chromaffin cells captured at 4000x magnification (scale bar = 300 nm). RCAN1ox chromaffin cells (black bars) have (c) a greater density
of mitochondria and (d) significantly smaller mitochondria when compared to wild-type controls (white bars). (e) RCAN1ox cells (red line)
have a higher frequency of smaller mitochondria when compared to wild-type controls (black line). 𝑛 = 9 cells from 3 animals for each
genotype, error bars represent the SEM, ∗𝑃 < 0.05, and ∗∗𝑃 < 0.01.

























Figure 3: RCAN1ox cells have altered mitochondrial membrane potential in response to ROS. Wild-type (light bars) and RCAN1ox (dark
bars) chromaffin cells were stained with the fluorescent mitochondrial membrane potential marker JC-1 under the following conditions:




(60 minutes/9 cells). Error bars
represent the SEM; ∗𝑃 < 0.05.





from 50 to 250 𝜇Mfor 18 hours. 41.5±9.8%of PC12RCAN1cells





3.7% of the control cells remained viable (Figure 6, 𝑃 <
0.01). This difference in cell viability was also observed when




, with 10.5 ± 2.8% of
PC12RCAN1 cells remaining viable compared to 32.5±9.0% of
treated control cells.These results in PC12RCAN1 cells confirm
that the effect of RCAN1 on cell susceptibility to oxidative
stress is due to cell autonomous effects of RCAN1.
4. Discussion
This study investigated the role of RCAN1 in regulating
mitochondrial function and susceptibility to oxidative stress
in a neuronal cell line and primary cells overexpressing
RCAN1. Elevated RCAN1 expression in PC12 cells resulted





. Similarly, primary neurons overexpress-





oxidative stress. Altered mitochondrial morphology, char-
acteristic of mitochondrial dysfunction, was observed via
an ultrastructural analysis of RCAN1ox cells and these cells
demonstrate altered mitochondrial membrane potential in
response to increased ROS levels. Thus, we demonstrate
that overexpressing RCAN1 in primarymammalian neuronal
cells causes significant changes to mitochondrial function
and oxidative stress responses.
Nebula, the Drosophila melanogaster ortholog of RCAN1,
is localized in mitochondria where it interacts with the
ADP/ATP translocator on the inner mitochondrial mem-
brane. The elevated ROS accumulation we observe in
PC12RCAN1 cells and which has been noted in neurons
overexpressing nebula [37] may be associated with altered
ADP/ATP translocator function resulting in decrease ATP
production [37], which in turn could affect oxidative phos-
phorylation and cause ROS accumulation [43, 44]. The
overexpression of RCAN1.1 in ST14A cells also affected
the ADP/ATP translocator and mitochondrial permeability
transition pore opening, resulting in mitochondrial degrada-
tion, autophagy, and reduced cell survival [45]. The altered
mitochondrial morphology observed in RCAN1ox chromaf-
fin cells could be related to the regulation of calcineurin
by RCAN1 and their various downstream targets. One
important calcineurin target is dynamin-related protein 1
(Drp1), a protein which increasesmitochondrial fission when
dephosphorylated and is dephosphorylated by calcineurin
[46]. Increased Drp1 phosphorylation in cells with high
RCAN1 expression could potentially underlie the altered
mitochondrial morphology observed in RCAN1ox cells.
Elevated RCAN1 expression resulted in decreased cell





exposure. Calcineurin activity is significantly atten-




and the inhibition of calcineurin
activity by exogenous pharmacological agents under these
conditions increases ROS-induced damage [11]. We postulate
that a similar inhibition of calcineurin activity in cells
overexpressing RCAN1 results in decreased cell viability. Cal-
cineurin activation plays a central role in controlling either
pro- or antiapoptotic cues in different cell types. Calcineurin
activity in neurons contributes to apoptosis associated with
glutamate excitotoxicity and ionophore-induced Ca2+ over-
loading [47, 48] while in cardiac myocytes calcineurin acti-





death [49].These contrasting effects of calcineurin activation



































Figure 4: Generation of a stable PC12 cell line overexpressing RCAN1, PC12RCAN1. (a) Diagrammatic representation of the generation of
the FLAG-fused RCAN1 construct, which was cloned into pGEM-T easy vector and finally ligated to the EcoR1 restriction site of pcDNA3
expression vector containing a pCMVpromoter. (b) Agarose gel electrophoresis of the PCR products from the 3 selected clones containing the
900 bp RCAN1-FLAG tag sequence, a water only (−) control, and (+) control using DNA encoding the pGEM-T/RCAN1-FLAG construct. (c)
Immunoblot against the FLAG tag in the 3 selected clones and a negative control lacking FLAG normalized to 𝛽-tubulin loading control. (d)
Immunocytochemistry of control PC12 and PC12RCAN1 cells with an antibody against RCAN1 demonstrates the elevated RCAN1 expression
in PC12RCAN1 cells (scale bar = 50 𝜇m).
highlight the potential complexity of the RCAN1/calcineurin
interaction in response to varying stress stimuli. While we
have not measured calcineurin activity during this study, our
previous work in chromaffin cells indicates that increased
RCAN1 expression effects cell functions via inhibition of
calcineurin [7]. It is therefore worthwhile to consider that
the effects of cell survival observed in cells overexpressing
RCAN1 may be a direct effect of the inhibition of calcineurin
activity.
Our findings inmammalian cells that RCAN1overexpres-
sion induces multiple facets of mitochondrial dysfunction
may have relevance to both DS and AD. In these disorders,
neuronal RCAN1 expression is significantly increased [2, 4,
16] and both disorders display a clear profile of neuronal
oxidative stress and mitochondrial dysfunction. Neuronal
oxidative stress is observed in mouse models of DS [31] and
in human DS neurons [29] while mitochondrial function is
diminished in this disorder [28]. Similarly, neuronal ROS
levels are higher in human tissue from AD patients [32, 33].
Our findings suggest that chronic overexpression of RCAN1
may have negative implications for mitochondrial function
and increase mitochondrial ROS production. Furthermore,
























Figure 5: RCAN1 overexpression increases mitochondrial ROS production. Representative images of (a) control and (b) PC12RCAN1 cells
stained with 100𝜇MMitoSOX Red at 20x magnification (scale bar = 50 𝜇m). (c) Quantification of MitoSOX fluorescence intensity revealed
that control cells (light bars) have significantly less mean fluorescence compared to PC12RCAN1 cells (dark bars) under basal conditions. The
addition of the antioxidant N-acetylcysteine (NAC) significantly reduces florescence in PC12RCAN1 cells while having no effect on control
cells. Data has been normalized to basal mean fluorescence in control cells and error bars represent SEM. 𝑛 = 30 cells from each group;
∗∗∗𝑃 < 0.001.
when cells are presentedwith an additional insult or challenge
such as oxidative stress in AD and DS, the increased RCAN1
levels may further exacerbate this oxidative stress. Indeed,
this may be the case in both DS and AD where neurons
have chronically elevated levels of oxidative stress [50, 51].
Our finding that the overexpression of RCAN1 regulates
mitochondrial morphology and function inmammalian cells
therefore provides additional insight into the function of
this protein with potential relevance for these related human
disorders.
Based on our observations in this study and our prior
knowledge of RCAN1 function and effectors of RCAN1
expression, we postulate that elevated RCAN1 expression
may have a detrimental effect on multiple facets of neuronal
function associated with mitochondrial function and AD
pathology (Figure 7). Cellular stress, including amyloid-𝛽
accumulation, can induce RCAN1 expression in neurons,
which inhibits the activity of the protein-phosphatase cal-
cineurin. Reduced calcineurin activity leads to the accumula-
tion of hyperphosphorylated tau and subsequent neurofibril-
lary tangles, a hallmark of AD brains. Further to this, we now
show that elevated RCAN1 expression leads to mitochondrial
dysfunction including altered mitochondrial morphology
and membrane potential and high mitochondrial ROS pro-
duction. This accumulation of ROS and ensuing oxidative
stress can have pathogenic consequences in mammalian
neurons that are strongly implicated in AD pathogenesis
and also induce a feed forward cycle by increasing RCAN1
expression further. Thus, our data provide a framework
for the involvement of RCAN1, mitochondrial dysfunction,
and oxidative stress that may be causative in AD progres-
sion.
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, fewer PC12RCAN1 cells
were viable when compared to control PC12 cells under the same
conditions. Data has been normalized to percentage of starting
viable cells for each group and error bars represent the SEM. 𝑛 = 13














Figure 7: Summative roles of RCAN1 in neurodegeneration and
cell function. Elevated amyloid-𝛽 levels in neuronal cells can lead
to elevated RCAN1 expression which inhibits calcineurin activity
resulting in accumulation of hyperphosphorylated tau protein. This
causes the formation of neurofibrillary tangles that lead to neurode-
generative disorders. We have further shown that elevated RCAN1
expression also leads to mitochondrial dysfunction, resulting in
elevated intracellular oxidative stress, both of which are implicated
in AD pathogenesis.
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